经导管肝动脉栓塞化疗联合系统性药物治疗肝细胞癌的研究进展  

Advances in clinical research on transarterial chemoembolization combining with systemic durgs in hepatocellular carcinoma

作　　者：杜蔚然 郭成祥 白雪莉[1] 梁廷波[1] Du Weiran;Guo Chengxiang;Bai Xueli;Liang Tingbo(Department of Hepatobiliary and Pancreatic Surgery,the First Affiliated Hospital Zhejiang University School of Medicine,Zhejiang Provincial Key Laboratory of Pancreatic Disease,Hangzhou 310003,China;Department of Medical Oncology,the First Affiliated Hospital Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院肝胆胰外科,浙江省胰腺病研究重点实验室,杭州310003 [2]浙江大学医学院附属第一医院肿瘤内科,杭州310003

出　　处：《中华肝胆外科杂志》2023年第12期949-955,共7页Chinese Journal of Hepatobiliary Surgery

基　　金：国家自然科学基金(82071867)。

摘　　要：肝细胞癌(HCC)是发病率及病死率均位居前列的消化系统恶性肿瘤之一。绝大多数中晚期HCC患者对于以经导管肝动脉栓塞化疗(TACE)为主的一系列治疗手段响应率低、远期生存差。近年来,分子靶向治疗、免疫治疗及二者联合TACE的治疗方案发展迅速。本文对TACE联合系统性药物治疗在HCC中的研究进展予以综述,并展望了未来HCC精准治疗方向。Hepatocellular carcinoma(HCC)is one of the malignant tumors of the digestive system with the highest morbidity and mortality.The vast majority of patients with intermdiate and advanced HCC have low response rates and poor long-term survival to a series of treatments mainly based on transcatheter arterial chemoembolization(TACE).In recent years,molecular targeted therapy,immunotherapy and their combination with TACE have developed rapidly.This article reviews the research progress of TACE combined with systemic drug therapy in HCC and looks forward to the future direction of precise treatment of HCC.

关 键 词：癌 肝细胞 经导管肝动脉栓塞化疗 靶向治疗 免疫治疗 

分 类 号：R735.7[医药卫生—肿瘤]